Health knowledge made personal
Join this community!
› Share page:
Search posts:

Facet Biotech and Biogen Idec plan for Phase III multiple sclerosis trial

Posted Nov 17 2009 10:20pm -

Aug 06, 2009 (Datamonitor via COMTEX) -- Facet Biotech, a developer of new oncology drugs, has announced its decision, along with its partner Biogen Idec, to continue planning for the Phase III trial of daclizumab high-yield process or DAC HYP in multiple sclerosis.

Continue to read by clicking here

Post a comment
Write a comment:

Related Searches